Oct. 26 Quick Takes: Triveni raises $92M for genetics-driven immunology pipeline
Plus: Sofinnova Partners closes digital medicine fund with $200M and more from BMS, Santhera and ImmunityBio
A merger of Polaris Partners-backed Amagma Therapeutics and Atlas Venture-backed Modify Therapeutics, Triveni Bio Inc. launched with a $92 million series A round co-led by Atlas and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris, Alexandria Venture Investments, and additional undisclosed investors.
The company’s lead program is a functional antibody targeting the serine proteases KLK5 and KLK7 to address barrier dysfunction, inflammation, and itch in atopic dermatitis, asthma and other immunology indications. In collaboration with Nashville Biosciences LLC, Triveni leverages human genetics data to identify rare disease targets with applications across subpopulations of common diseases. The company plans to nominate two more development candidates in 2024, and the funds are expected to take the KLK5/KLK7-targeting lead program to a Phase IIa study...